Recent Pfizer Press Releases

  • 12/21/07 2:05 pm EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) issued for dalbavancin HCl, Pfizer’s once-weekly two-dose antibiotic under FDA review for the treatment of adult patients with complicated skin and skin structure infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The FDA recently published a draft guidancemore...
  • 12/21/07 10:13 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc recently conducted a comparative analysis of the tropism assays TrofileTM, provided by Monogram Biosciences, and SensiTropTM, provided by Pathway Diagnostics. This analysis of 100 treatment experienced patient samples showed that the SensiTrop results were discordant with the results obtained using Trofile, which was used and clinically validated in the SelzentryTM (maraviroc) clinical trials.more...
  • 12/18/07 8:00 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer (NYSE:PFE) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) has expired, and that it has received clearance from the Federal Cartel Office of Germany (FCO), in each case in connection with its offer to purchase all of the outstanding shares of common stock of Coley Pharmaceutical Group, Inc. (Nasdaq:COLY). Expiration of the waiting period undermore...
  • 12/18/07 8:00 am EST

    Acquisition Will Provide Innovative Biotherapeutics Technology Platform and Complementary Product Candidates in Oncology and Diabetes

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today it has entered into an agreement to acquire CovX, a privately-held biotherapeutics company specializing in preclinical oncology and metabolic research and a developer of a biotherapeutics technology platform that will enhance Pfizer’s biologic portfolio. “The acquisition of CovX is a further step in Pfizer’s strategy to acquire and identify new product candidatesmore...
  • 12/17/07 3:26 pm EST

    Represents 10 Percent Dividend Increase

    NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc today declared a 32-cent first–quarter, 2008, dividend on the company’s common stock, payable March 4, 2008, to shareholders of record at the close of business on February 8, 2008. Pfizer increased the dividend by approximately 10 percent from 29 cents to 32 cents per share as part of the Company’s continued commitment to enhancing shareholder returnmore...
  • 12/5/07 7:00 am EST

    Proprietary Delta Opioid Receptor Agonists Offer Promise to Treat Range of Inflammatory, Neuropathic and Acute Pain Conditions

    Adolor to Host Conference Call

    NEW YORK & EXTON, Pa.--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Adolor Corporation (Nasdaq: ADLR) announced today an exclusive worldwide collaboration to develop and commercialize novel compounds, ADL5859 and ADL5747, for the treatment of pain. Both compounds are proprietary Delta opioid receptor agonist candidates with the potential to treat a wide range of inflammatory, neuropathic and acute pain conditions. The companies will form amore...
  • 11/30/07 8:30 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced the commencement of its cash tender offer for all outstanding shares of common stock of Coley Pharmaceutical Group, Inc. (Nasdaq:COLY) for $8.00 per share. The tender offer is being made pursuant to an Offer to Purchase, dated November 30, 2007, and in connection with the Agreement and Plan of Merger, dated November 15, 2007, by and among Pfizer, Corvette Acquisition Corp., an indirectmore...
  • 11/16/07 1:22 pm EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a meeting with investment analysts to be held on Friday, November 30, at 12:00p.m. Hong Kong Time (Thursday, November 29, at 11:00p.m. Eastern Daylight Savings Time). The analyst meeting will include a presentation by Dr. Martin Mackay, President, Pfizer Global Research and Development. To view and listen to the webcast, visit ourmore...
  • 11/16/07 8:31 am EST

    Acquisition Will Expand Pfizers Investment in Vaccines, Broaden Scope of Research in a Number of Key Therapeutic Areas

    NEW YORK & WELLESLEY, Mass.--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) announced today it has entered into an agreement to acquire Coley Pharmaceutical Group, Inc. (NASDAQ: COLY), a publicly-held biopharmaceutical company specializing in vaccine adjuvant technology and a new class of immunomodulatory drug candidates designed to fight cancers, allergy and asthma disorders, and autoimmune diseases. Under the terms of the agreement, Pfizer will make amore...
  • 11/13/07 8:30 am EST
    NEW YORK & SAN CARLOS, Calif.--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Nektar Therapeutics (NASDAQ: NKTR) announced today that the two companies have resolved all outstanding contractual issues in connection with Exubera® and Nektar’s innovative Next Generation Inhaled Insulin (NGI) product currently in Phase 1 clinical development. Under the terms of the agreement, Nektar will receive a one-time payment of $135 million frommore...